A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University, has succeeded in the diagnosis ...

A group at Niigata University succeeded in the early diagnosis of leptomeningeal disease in H3K27M-mutant diffuse midline ...

Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA ...

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of ...

In connection with the SEPA executed in December 2023 and amended in January 2024, Calidi was granted the option to sell up to $25 million of common stock over a three-year period, subject to certain ...

IGFBP2表达评估idh突变的胶质瘤患者生存 （IGFBP2 expression predicts IDH-mutant glioma patient survival） ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a ca ...

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of ...

Similar findings with no significant association seen when accounting for hormone therapy status and duration of use.

FastGlioma vs image- and fluorescence-guided adjuncts better detected tumor infiltration during surgery by a large margin.

male rats [subjected to Blue 2], Blue 2 cannot be considered safe for human consumption," the paper reported. "Since Blue 2 ...

Dr. Clark Chen, a neurosurgeon at Rhode Island Hospital, has become the first in the state to utilize GammaTile® Therapy, a bioresorbable ...